Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J R Ballinger

Showing results (41-50 of 82) with videos related to

Pageof 9
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1993
Formulation of technetium-99m-aerosol colloid with improved delivery efficiency for lung ventilation imagingJ R Ballinger, T W Andrey, I Boxen, et al.
Bioconjugate Chemistry|September 30, 1999
Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technologyR Dunn-Dufault, A Pollak, J R Thornback, et al.
Biochemical Pharmacology|October 6, 1997
Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromaticsT Melo, H A Hua, J R Ballinger, et al.
International Journal of Cancer|March 23, 2000
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layersJ K Tunggal, T Melo, J R Ballinger, et al.
Journal of Nuclear Medicine Technology|June 3, 1999
External radioactive reference markers in SPECT imaging of the dopamine systemD C Vines, B D Ivo, J R Ballinger, et al.
Annals of Nuclear Medicine|February 1, 1993
Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humansH Toyama, M Ichise, J R Ballinger, et al.
Clinical Nuclear Medicine|June 1, 1990
Cerebral perfusion imaging with technetium-99m HMPAO following cerebral trauma. Initial experienceR H Reid, K Y Gulenchyn, J R Ballinger, et al.
British Journal of Urology|February 1, 1995
A novel anti-seminoma monoclonal antibody (M2A) labelled with technetium-99m: potential application for radioimmunoscintigraphyA Marks, J R Ballinger, R M Reilly, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 1993
Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's diseaseM Ichise, H Toyama, L Fornazzari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1997
Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjectsM Ichise, J R Ballinger, D Vines, et al.
Pageof 9

Showing results (41-50 of 82) with videos related to

Sort By:
Pageof 9
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 1, 1993
Formulation of technetium-99m-aerosol colloid with improved delivery efficiency for lung ventilation imagingJ R Ballinger, T W Andrey, I Boxen, et al.
Bioconjugate Chemistry|September 30, 1999
Convenient preparation of no-carrier-added technetium-99m radiopharmaceuticals using solid-phase technologyR Dunn-Dufault, A Pollak, J R Thornback, et al.
Biochemical Pharmacology|October 6, 1997
Modifying the in vitro accumulation of BMS181321, a technetium-99m-nitroimidazole, with unlabelled nitroaromaticsT Melo, H A Hua, J R Ballinger, et al.
International Journal of Cancer|March 23, 2000
The influence of expression of P-glycoprotein on the penetration of anticancer drugs through multicellular layersJ K Tunggal, T Melo, J R Ballinger, et al.
Journal of Nuclear Medicine Technology|June 3, 1999
External radioactive reference markers in SPECT imaging of the dopamine systemD C Vines, B D Ivo, J R Ballinger, et al.
Annals of Nuclear Medicine|February 1, 1993
Dopamine D2 receptor SPECT imaging: basic in vivo characteristics and clinical applications of 123I-IBZM in humansH Toyama, M Ichise, J R Ballinger, et al.
Clinical Nuclear Medicine|June 1, 1990
Cerebral perfusion imaging with technetium-99m HMPAO following cerebral trauma. Initial experienceR H Reid, K Y Gulenchyn, J R Ballinger, et al.
British Journal of Urology|February 1, 1995
A novel anti-seminoma monoclonal antibody (M2A) labelled with technetium-99m: potential application for radioimmunoscintigraphyA Marks, J R Ballinger, R M Reilly, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 1, 1993
Iodine-123-IBZM dopamine D2 receptor and technetium-99m-HMPAO brain perfusion SPECT in the evaluation of patients with and subjects at risk for Huntington's diseaseM Ichise, H Toyama, L Fornazzari, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|January 1, 1997
Simplified quantification and reproducibility studies of dopamine D2-receptor binding with iodine-123-IBF SPECT in healthy subjectsM Ichise, J R Ballinger, D Vines, et al.
Pageof 9